jain.com

Director Michael Bucella insider stock purchase

Company: TeraWulf

Subject kind
personnel
Statement date
2026-09-17
Promised by
2026-09-15
Promised amount
6085.0 shares
Current status
not yet verifiable

The claim, verbatim

Director Michael Bucella acquired 6,085 shares at an average cost of $14.79 per share on September 15, 2026

Source (primary)

TeraWulf (NASDAQ:WULF) Shares Gap Up Following Insider Buying Activity - MarketBeat (-, news_article)
View cached copy (2026-09-20)Live source ↗

Quote: “Director Michael Bucella acquired 6,085 shares of the stock in a transaction dated Tuesday, September 15th. The stock was acquired at an average cost of $14.79 per share, with a total value of $89,997.15.”

How we checked this

Checked on September 25, 2026. The cited source supports every part of this claim.

The article states that Director Michael Bucella bought 6,085 shares at an average of $14.79 in a transaction dated Tuesday, September 15th. The article's September 17, 2026 dateline fixes the year.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://www.marketbeat.com/instant-alerts/price-terawulf-nasdaq-wulf-shares-gap-up-following-insider-buying-activity-2026-09-17/) in full (16,816 characters, retrieved September 20, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms TeraWulf (NASDAQ:WULF) Shares Gap Up Following Insider Buying Activity - MarketBeat

Quote: “Director Michael Bucella acquired 6,085 shares of the stock in a transaction dated Tuesday, September 15th. The stock was acquired at an average cost of $14.79 per share, with a total value of $89,997.15.”

View cached copy (2026-09-20)Live source ↗

Record of changes

September 20, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 21, 2026 — not yet verifiable
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.